Andrew T Hughes Selected Research

Homogentisic Acid

9/2022	Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
9/2022	Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
9/2020	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
5/2020	The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma.
1/2020	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
1/2020	Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
1/2020	Nitisinone causes acquired tyrosinosis in alkaptonuria.
1/2020	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
12/2019	Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
7/2019	Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew T Hughes Research Topics

Disease

20	Alkaptonuria 09/2022 - 01/2015
4	Ochronosis 09/2020 - 01/2020
3	Disease Progression 01/2022 - 01/2020
2	Tyrosinemias (Tyrosinemia) 01/2020 - 01/2019
2	Inborn Genetic Diseases (Disease, Hereditary) 12/2019 - 01/2015
1	Phenylketonurias (Phenylketonuria) 09/2022
1	Tyrosinosis 01/2020
1	Osteoarthritis 09/2015

Drug/Important Bio-Agent (IBA)

15	Homogentisic AcidIBA 09/2022 - 01/2015
14	nitisinone (Orfadin)FDA Link 09/2022 - 01/2015
13	Tyrosine (L-Tyrosine)FDA Link 09/2022 - 01/2015
5	Homogentisate 1,2-Dioxygenase (Homogentisate 1,2 Dioxygenase)IBA 07/2022 - 09/2015
4	Phenylalanine (L-Phenylalanine)FDA Link 09/2022 - 01/2020
2	EnzymesIBA 07/2022 - 07/2022
2	Biomarkers (Surrogate Marker)IBA 05/2020 - 09/2015
1	4-hydroxyphenyllactic acidIBA 09/2022
1	4-hydroxyphenylpyruvic acidIBA 09/2022
1	Complement System Proteins (Complement)IBA 09/2022
1	Proteins (Proteins, Gene)FDA Link 05/2020
1	SeleniumIBA 05/2020
1	Serum AlbuminIBA 05/2020
1	NitrogenIBA 05/2020
1	Vitamin D FDA LinkGeneric 05/2020
1	ZincIBA 05/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 05/2020
1	Dietary ProteinsIBA 01/2020
1	Amino Acids FDA Link 01/2020

Therapy/Procedure

6	Therapeutics 09/2020 - 09/2015
1	Diet Therapy (Therapy, Diet) 01/2020